• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病发病年龄对应的左旋多巴诱导的异动症发生率

Levodopa-dyskinesia incidence by age of Parkinson's disease onset.

作者信息

Kumar Neeraj, Van Gerpen Jay A, Bower James H, Ahlskog J Eric

机构信息

Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA.

出版信息

Mov Disord. 2005 Mar;20(3):342-4. doi: 10.1002/mds.20360.

DOI:10.1002/mds.20360
PMID:15580606
Abstract

We assessed the 5-year risk of levodopa-induced dyskinesias by age of Parkinson's disease (PD) onset in a population-based cohort. The medical records linkage system of the Rochester Epidemiology project was used to identify residents of Olmsted County, Minnesota, with incident PD for the period 1976 through 1990. In this population-based study, the 5-year dyskinesia incidence declined with age. With PD onset after 70 years of age, the incidence was 16%. With onset from 40 to 59 years of age, the incidence was higher at 50%. These incidence data may overestimate the functional importance, because patients with minimal or reversible dyskinesias were counted.

摘要

我们在一项基于人群的队列研究中,按帕金森病(PD)发病年龄评估了左旋多巴诱发异动症的5年风险。利用罗切斯特流行病学项目的医疗记录链接系统,识别出明尼苏达州奥尔姆斯特德县1976年至1990年期间新发PD的居民。在这项基于人群的研究中,5年异动症发病率随年龄下降。PD发病年龄在70岁以后,发病率为16%。发病年龄在40至59岁之间,发病率较高,为50%。这些发病率数据可能高估了功能重要性,因为纳入了轻度或可逆性异动症患者。

相似文献

1
Levodopa-dyskinesia incidence by age of Parkinson's disease onset.帕金森病发病年龄对应的左旋多巴诱导的异动症发生率
Mov Disord. 2005 Mar;20(3):342-4. doi: 10.1002/mds.20360.
2
Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.1976 - 1990年明尼苏达州奥尔姆斯特德县帕金森病患者中左旋多巴相关异动症的风险
Arch Neurol. 2006 Feb;63(2):205-9. doi: 10.1001/archneur.63.2.205.
3
[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].[帕金森病患者左旋多巴诱发异动症的社会和经济成本]
Rev Neurol (Paris). 2001 May;157(5):507-14.
4
A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.一项基于医院的研究:555例接受左旋多巴治疗的帕金森病患者发生运动并发症的危险因素。
Clin Neurol Neurosurg. 2006 Dec;108(8):726-32. doi: 10.1016/j.clineuro.2006.02.002. Epub 2006 Mar 27.
5
Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.中国特发性帕金森病患者运动并发症发生的危险因素
J Clin Neurosci. 2009 Aug;16(8):1034-7. doi: 10.1016/j.jocn.2008.10.015. Epub 2009 May 9.
6
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.早期帕金森病中添加罗匹尼罗缓释或额外左旋多巴引起的运动障碍发作。
Mov Disord. 2010 May 15;25(7):858-66. doi: 10.1002/mds.22890.
7
Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.异动症可预测帕金森病患者左旋多巴单药治疗中运动反应波动的发生。
Parkinsonism Relat Disord. 2005 May;11(3):151-5. doi: 10.1016/j.parkreldis.2004.10.002.
8
Current controversies: levodopa in the treatment of Parkinson's disease.当前争议:左旋多巴在帕金森病治疗中的应用
Mov Disord. 2005 May;20(5):642-3; author reply 643-4. doi: 10.1002/mds.20444.
9
Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease.疾病与治疗的并发症:年轻与老年帕金森病患者的比较
Ann Clin Lab Sci. 1996 Sep-Oct;26(5):389-95.
10
[Incidence and determinants of levodopa-induced dyskinesia in a retrospective cohort of Mexican patients with Parkinson's disease].[墨西哥帕金森病患者回顾性队列中左旋多巴诱导的运动障碍的发生率及决定因素]
Rev Invest Clin. 2012 May-Jun;64(3):220-6.

引用本文的文献

1
Identifying Risk Factors and Constructing Predictive Models for Wearing-Off and Dyskinesia in Chinese Patients With Parkinson's Disease on Long-Term Levodopa Therapy.识别长期接受左旋多巴治疗的中国帕金森病患者剂末现象和异动症的风险因素并构建预测模型
CNS Neurosci Ther. 2025 Aug;31(8):e70544. doi: 10.1111/cns.70544.
2
Advancing age and sex modulate antidyskinetic efficacy of striatal Ca1.3 gene therapy in a rat model of Parkinson's disease.在帕金森病大鼠模型中,年龄增长和性别会调节纹状体Ca1.3基因治疗的抗运动障碍疗效。
Neurobiol Aging. 2025 May;149:54-66. doi: 10.1016/j.neurobiolaging.2025.02.003. Epub 2025 Feb 20.
3
Neuroinflammation and Dyskinesia: A Possible Causative Relationship?
神经炎症与运动障碍:一种可能的因果关系?
Brain Sci. 2024 May 20;14(5):514. doi: 10.3390/brainsci14050514.
4
Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study.左旋多巴诱导的运动障碍在帕金森病中很常见,且影响生活质量:一项为期 5 年的随访研究。
Mov Disord Clin Pract. 2024 Jul;11(7):830-849. doi: 10.1002/mdc3.14056. Epub 2024 May 15.
5
Levodopa-Induced Dyskinesias in Parkinson's Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions.帕金森病中的左旋多巴诱发异动症:病理生理学、临床表现、治疗管理策略及未来方向概述
J Clin Med. 2023 Jun 30;12(13):4427. doi: 10.3390/jcm12134427.
6
PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.PT320,一种长效 GLP-1 受体激动剂,可改善帕金森病小鼠模型中 L-DOPA 诱导的运动障碍。
Int J Mol Sci. 2023 Feb 28;24(5):4687. doi: 10.3390/ijms24054687.
7
Deep brain stimulation in Early Onset Parkinson's disease.早期帕金森病的脑深部电刺激治疗
Front Neurol. 2022 Nov 17;13:1041449. doi: 10.3389/fneur.2022.1041449. eCollection 2022.
8
Age Cutoff for Early-Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease.早发性帕金森病的年龄界定:国际帕金森病和运动障碍协会早发性帕金森病特别工作组的建议
Mov Disord Clin Pract. 2022 Sep 10;9(7):869-878. doi: 10.1002/mdc3.13523. eCollection 2022 Oct.
9
Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats.腹腔内给予毛喉素可逆转 PINK1 敲除大鼠的运动症状和中脑多巴胺神经元的丢失。
J Parkinsons Dis. 2022;12(3):831-850. doi: 10.3233/JPD-213016.
10
Effects of Aging on Levo-Dihydroxyphenylalanine- Induced Dyskinesia in a Rat Model of Parkinson's Disease.衰老对帕金森病大鼠模型中左旋二羟基苯丙氨酸诱导的运动障碍的影响
Front Aging Neurosci. 2021 May 13;13:650350. doi: 10.3389/fnagi.2021.650350. eCollection 2021.